Skip to Content

Ticlopidine Dosage

Applies to the following strengths: 250 mg

The information at is not a substitute for medical advice. Always consult your doctor or pharmacist.

Usual Adult Dose for Cerebral Thrombosis/Embolism

250 mg orally twice a day.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available


The dosage of ticlopidine may need to be reduced or discontinued in patients with moderate to severe renal failure if hematologic side effects occur.

Safety and effectiveness have not been established in pediatric patients (less than 18 years of age).


Data not available

Other Comments

Ticlopidine should be taken with food to minimize gastrointestinal side effects.

In patients receiving an intracoronary stent, following successful stent implantation, ticlopidine therapy may be continued for up to 30 days. However, the results of one study (ATLAST trial) suggest that the frequency of stent thrombosis and other adverse ischemic events remains low even when ticlopidine is discontinued after 2 weeks of therapy. However, the results of another prospective observational cohort study indicate that in patients receiving a drug eluding stent, therapy with either ticlopidine or clopidogrel, in addition to aspirin, should be continued for at least 6 months after stent implantation in order to lower the risk of stent thrombosis. However, the benefit of continuing therapy beyond 6 months is equivocal. Aspirin therapy should be maintained indefinitely.

Ticlopidine may cause life-threatening hematological adverse reactions including neutropenia/agranulocytosis and thrombotic thrombocytopenic purpura (TTP).

It has been suggested that patients receiving ticlopidine should be monitored with liver function tests along with complete blood cell counts.